Search
Spotlight
CME Opportunities
CME Opportunities
Specialty
View More
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
News
OncClub
All Oncology News
OncClub
All Oncology News
Media
Insights
MedNews Week
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
Insights
MedNews Week
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
Conferences
Conference Coverage
Conference Listing
Conference Coverage
Conference Listing
Events
Giants of Cancer Care
CME/CE
Scientific Interchanges
State of the Science Summit / IPC
National Fellows Forum
Webinars
Giants of Cancer Care
CME/CE
Scientific Interchanges
State of the Science Summit / IPC
National Fellows Forum
Webinars
Partners
Publications
Resources
Consensus Viewpoints
OncLive App
Interactive Tools
Sponsored
Consensus Viewpoints
OncLive App
Interactive Tools
Sponsored
Biomarker Consortium
Subscribe
Search
Spotlight
CME Opportunities
Specialty
See All >
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
Role of Cytoreductive Nephrectomy in mRCC
EP. 1: Role of Cytoreductive Nephrectomy in mRCC
April 14th 2020
EP. 2: Cytoreductive Nephrectomy in mRCC: Current Data
April 14th 2020
EP. 3: Cytoreductive Nephrectomy After I/O in mRCC
April 14th 2020
EP. 4: Ipilimumab/Nivolumab in First-Line mRCC
April 14th 2020
EP. 5: iRECIST Criteria and First-Line Treatment of mRCC
April 14th 2020
EP. 6: Ipilimumab/Nivolumab for Favorable-Risk mRCC
April 14th 2020
EP. 7: SBRT in Combination With Ipilimumab/Nivolumab in mRCC
April 14th 2020
EP. 8: VEGF-TKI Therapy in First-Line mRCC
April 14th 2020
EP. 9: IMDC Criteria and Targeted Therapy in mRCC
April 14th 2020
EP. 10: mRCC: Resistance to VEGF and I/O
April 14th 2020
EP. 11: Second-Line Therapy After I/O in mRCC
April 14th 2020
EP. 12: VEGF TKI Therapy After I/O in mRCC
April 14th 2020
EP. 13: Combination Therapies to Overcome Resistance in mRCC
April 14th 2020
EP. 14: Progress in First-Line mRCC
April 14th 2020
EP. 15: Promising Second-Line Therapies for mRCC
April 14th 2020
EP. 16: Other Trials of Interest in Renal Cancers
April 14th 2020
x